Table 5. Frequency distribution of the IREB2 and FAM13A haplotypes and results of logistic regression analysis for association with COPD, LC, COPD+LC with COPD cases and controls.

SNP	Frequency of genotypes		OR (95% CI)	P	Frequency of genotypes	OR (95% CI)	P	Frequency of genotypes	OR (95% CI)	P
	Controls	COPD			LC			COPD with LC+COPD
IREB2
AAAT	0.34	0.31	0.87 [0.59–1.29]	0.479	0.39	1.51 [1.16–1.97]	0.00211	0.35	1.05 [0.76–1.44]	0.761
GAAT	0.27	0.28	1.06 [0.70–1.58]	0.793	0.27	0.91 [0.75–1.31]	0.950	0.26	0.97 [0.68–1.65]	0.795
GGGC	0.24	0.16	0.61 [0.38–0.98]	0.039	0.20	0.79 [0.59–1.07]	0.134	0.18	0.70 [0.48–1.02]	0.065
GAAC	0.15	0.17	1.14 [0.69–1.86]	0.612	0.13	0.84 [0.59–1.21]	0.356	0.16	1.80 [0.72–1.64]	0.705
FAM13A
CCT	0.43	0.36	0.76 [0.52–1.1]	0.143	0.45	1.09 [0.85–1.4]	0.497	0.37	0.78 [0.57–1.70]	0.123
TTC	0.37	0.52	1.82 [1.26–2.63]	0.00131	0.42	1.27 [0.96–1.6]	0.103	0.51	1.76 [1.29–2.39]	0.00031
TTT	0.12	0.10	0.83 [0.45–1.49]	0.511	0.08	0.63 [0.41–0.96]	0.032	0.08	0.64 [0.38–1.09]	0.097
CTT	0.03	0.02	0.65 [0.19–2.23]	0.499	0.04	1.34 [0.68–2.65]	0.391	0.03	0.92 [0.37–2.27]	0.860

COPD—chronic obstructive pulmonary disease; LC—lung cancer; COPD with LC+COPD: the associations with COPD were studied twice: using pure COPD group and COPD with 40% admixture of subjects with concomitant LC.

OR (95% CI), odds ratio (95% confidence interval).

¹Result statistically significant (P < 0.0125, after Bonferroni correction).